Ispanija - ispanų - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan ire healthcare limited - ibuprofeno - suspensiÓn oral - 20 mg/ml - ibuprofeno 20 mg - ibuprofeno

Europos Sąjunga - ispanų - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - la esclerosis múltiple remitente-recurrente - inmunosupresores - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Europos Sąjunga - ispanų - EMA (European Medicines Agency)

viatris limited - la pirfenidona - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - inmunosupresores - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Ekvadoras - ispanų - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

mylan pharma gmbh suiza - clozapina básica (cas5786-21-0) 100,00 mg - comprimidos - cada comprimido contiene: clozapina básica (cas5786-21-0) 100,00 mg

Europos Sąjunga - ispanų - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.